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One hundred fifty-one Escherichia coli strains resistant to cefotaxime and24
ceftazidime were isolated during a prospective surveillance study. These strains were25
characterized by clinical, microbiological, and molecular analyses and were distributed26
into four clusters of 103, 11, 6 and 5 isolates, and 25 unrelated strains. The principal27
cluster was isolated from urine, wound, blood, and other samples in three hospitals,28
eight nursing homes, and a community healthcare center. This cluster was associated29
with both nosocomial (65%) and community acquired infections (35%). Most strains30
were resistant to ciprofloxacin, gentamicin, tobramycin, cefepime, amoxicillin/31
clavulanic acid, and trimethoprim/ sulfamethoxazole, but susceptible to imipenem. All32
isolates from the four clusters expressed the extended-spectrum β-lactamase (ESBL) 33
CTX-M-15. This enzyme was also present in 8 (30.8%) of the 26 unrelated isolates.34
The other ESBLs, CTX-M-14 and CTX-M-32, were detected in 5 and 7 cases,35
respectively, but they were detected in individual E. coli isolates only. In three clusters,36
blaCTX-M-15 alleles were linked to an ISEcp1-like element (implicated in their37
mobilization), while in eight strains of cluster II an IS26 element preceded the blaCTX-M-38
15 allele. An additional pool of resistance genes included tetA, drfA14 or dfrA17, sul139
or sul2, aac (6´)-1b, and aac (3)-IIb. All except one of the 27 isolates tested for genetic40
virulence markers harbored the same three virulence genes: iutA and fyuA41
(siderophores), and traT (serum survival factor). Epidemic or occasional isolates of42
cefotaxime and ceftazidime resistant E. coli can spread between distinct health facilities43





The production of extended spectrum β-lactamases (ESBLs) is one of the major 48
sources of resistance to extended spectrum cephalosporins in Enterobacteriaceae (16).49
Classically, plasmid-mediated ESBL enzymes have been of the TEM and SHV types,50
but in recent years, CTX-M-type ESBLs have been increasingly found throughout the51
world (1). CTX-M enzymes predominantly hydrolyze cefotaxime but are weakly active52
against ceftazidime. However, some ESBLs of the CTX-M family display increased53
hydrolytic activities against ceftazidime, as is the case for CTX-M-15 (24) and CTX-M-54
32 (4).55
In recent years, ESBL production in Enterobacteriaceae, particularly56
Escherichia coli, has significantly increased in several countries, including Spain57
(6,21,30). This increase is primarily due to the spread of CTX-M-type ESBLs (25).58
ESBL dissemination in E. coli is usually due to plasmid transmission between unrelated59
strains (9), while clonal spreading is more frequent in other Enterobacteriaceae, such as60
Klebsiella pneumoniae (23). However, outbreaks of ESBL-producing E. coli clones61
have recently been described (2,15,18,19,32). In Spain the proportion of CTX-M-E.62
coli producers is rapidly increasing in both nosocomial and community acquired63
infections (21,25).64
We have observed an apparent and alarming increase of cefotaxime- and65
ceftazidime-resistant strains amongst the E. coli isolates submitted to our laboratory.66
These events prompted the present study in which we describe the emergence and67
spread of high-level cefotaxime and ceftazidime resistant E. coli isolates, their complex68
molecular epidemiology, and the characterization of several clusters of multi-drug69
resistant CTX-M-15-producing E. coli isolates. Epidemic strains were detected in70
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patients admitted to hospitals and nursing homes for the elderly, as well as in patients71




A prospective surveillance study of infections caused by ESBL-producing E. coli is76
currently ongoing in the Autonomous Community of Madrid, Spain. Three hospitals77
located in three separate geographic areas participated in the study and included78
Hospital Gregorio Marañón (estimated catchment population of 650,000), Hospital79
Fundación de Alcorcón (estimated catchment population of 250,000, including eight80
associated nursing homes), Hospital Severo Ochoa de Leganés (estimated catchment81
population of 380,000), and a community healthcare center, Centro de Especialidades82
Argüelles. All collected the inital E. coli isolates that displayed ESBL production and83
sent them to the Centro Nacional de Microbiología (CNM), a public-health reference84
institution, to confirm ESBL production and to study the molecular epidemiology of the85
isolates and the ESBL type. Here we describe the analysis of all ESBL-producing E.86
coli, isolated between January 2004 and August 2005, which exhibited resistance to87
cefotaxime (>32 μg/mL) and ceftazidime (≥16 μg/mL).   88
89
Infections and patient characteristics90
The participating institutions collected the following information: personal91
patient data (code, age, sex, clinical diagnosis, and risk factors), hospital and92
departmental data, and isolate data (clinical sample and antimicrobial susceptibility).93
This information was entered into the Whonet software program, a free microbiological94
database (WHO Collaborating Center for the Surveillance of Antibiotic Resistance).95
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Patients with acquired community infections were the outpatients and those who96
had a positive culture at the time of or within 48 hours of hospitalization, in both cases97
they have not been previously in a healthcare setting for 1 month.98
99
Antimicrobial susceptibility testing and ESBL production detection100
E. coli isolates were identified and antibiotic susceptibility was tested according101
to standard microbiological procedures performed in each clinical laboratory. At the102
CNM, isolates were subcultured in both Columbia blood agar and McConkey agar to103
ensure viability and purity. The identification of all isolates was confirmed according to104
standard microbiological methods; susceptibility testing was initially carried out by105
microdilution (BD Phoenix Automated Microbiology System; Becton-Dickinson106
Diagnosis, Sparks, MD, USA) and the disk-diffusion reference method (5). The107
antimicrobial agents tested were as follows: ampicillin, amoxicillin/clavulanic acid,108
piperacillin/tazobactam, cefoxitin, cefotaxime, ceftazidime, cefepime, amikacin,109
gentamicin, tobramicin, ciprofloxacin, imipenem, and trimetoprim/sulfametoxazole.110
ESBL production was confirmed as described by the Clinical Laboratory Standards111
Institute (CLSI) (5); inhibition zones obtained using disks that contained cefotaxime (30112
μg) and ceftazidime (30 μg) were compared with those containing 113
cefotaxime/clavulanic acid (30/10 μg) and ceftazidime/clavulanic acid (30/10 μg) 114
(Oxoid, Madrid, Spain), respectively. In addition, the minimal inhibitory concentrations115
(MICs) to cefotaxime and cefotaxime/clavulanic acid, as well as to ceftazidime and116
ceftazidime/clavulanic acid, were determined by the E-test method (AB-Biodisk, Solna,117
Sweden). Antimicrobial susceptibility results were interpreted according to the118
breakpoints recommended by the CLSI (5). E. coli ATCC 25922 and Pseudomonas119
aeruginosa ATCC 27853 were used as quality control strains.120
Molecular epidemiology121
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The molecular epidemiology of E. coli isolates that were resistant to cefotaxime122
and ceftazidime was determined by pulsed-field gel electrophoresis (PFGE). Total123
bacterial DNA was digested with XbaI (MBI Fermentas, Vilnius, Lithuania), and DNA124
fragments were separated on a 1% agarose gel in 0.5 X TBE buffer using the CHEF125
Mapper apparatus (BioRad, Madrid, Spain). The conditions were as follows: 14°C, 6126
V/cm, pulse 2-54 s, and 24 h. Gels were stained with ethidium bromide and127
photographed under ultraviolet (UV) light. Genetic similarity was calculated by the128
unweighted pair group method using arithmetic averages (UPGMA) and presented in a129
dendrogram. Similarity was calculated by Dice’s coefficients with a tolerance of 1.8%130
(Fingerprinting II Software, BioRad). Well-resolved bands that corresponded to131
fragments exceeding 48.5 kb were included in the computer analysis.132
Isoelectric focusing133
Isoelectric focusing was carried out on a total of 73 E. coli isolates representing134
the major clones identified by PFGE. Bacteria, exponentially growing at 37°C in Luria-135
Bertani medium, were harvested, and cell-free lysates were prepared by sonication.136
Isoelectric focusing was performed by applying this crude extract to Phast gels (pH = 3-137
9) in a Phastsystem apparatus (Pharmacia AB, Uppsala, Sweden) (10).  β-lactamases138
with known pIs of 5.9, 5.4, 7.6, and 8.1 were used in parallel as controls. Gels were139
stained with 500 µg nitrocefin/mL (Oxoid) to identify β-lactamase bands.   140
Molecular analysis of ESBLs141
Based on both antibiotic resistance profiles and pI values, molecular142
identification of β-lactamases was carried out by PCR amplification and DNA 143
sequencing.  All β-lactamases detected by isoelectric focusing were characterized by 144
molecular methods. Genomic DNA from wild-type isolates was used as a template for145
PCR. ESBL amplification was performed with the appropriate primers and cycling146
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conditions for the TEM, SHV, CTX-M, OXA-1, OXA-2, and OXA-10 β-lactamase 147
groups, as described elsewhere (3,22,28). The following primers were designed to148
amplify and sequence the blaCTX-M-15 gene under standard conditions (CTX-M-15-F: 5´-149
ATG GTT AAA AAA TCA CTG CG- 3´ and CTX-M-15-R: 5´- TTA CAA ACC GTT150
GGT GAC G- 3´). PCR products were separated on 0.8% agarose gels, stained with151
ethidium bromide, visualized under UV light, further purified using the QIAquick PCR152
purification kit (Qiagen, Hilden, Germany), and sequenced using an ABI Prism 377153
automated sequencer (Perkin-Elmer, Norwalk, Conn).154
Linkage of blaCTX-M-15 alleles with ISEcp1-like elements, previously implicated155
in their expression and mobilization (13), was confirmed with primers PROM+ and156
PRECTX-M-3B as described previously (24,32). In addition, specific primers were157
used to amplify a 400-bp fragment spanning the link between IS26 (inserted between158
ISEcp1 and blaCTX-M-15) and blaCTX-M-15; this fragment is believed to be characteristic of159
the epidemic E. coli strain A, a CTX-M-15 producer from the United Kingdom (32).160
Identification of additional resistance genes161
Based on antibiotic resistance profiles, additional mechanisms of antibiotic162
resistance were studied in 10 multiresistant CTX-M-15-producing isolates. Molecular163
identification of sul1, sul2, tetA, aac6-1´b, aac3-IIb, dfrA14, and dfrA17 genes was164
carried out by PCR amplification and DNA sequencing using primers previously165
described (8,14,15,20). In addition, the acrR gene of the AcrAB efflux system was166
amplified, including the promoter-operator region, as described elsewhere (31).167
Virulence factors168
Twenty seven isolates from different clinical samples belonging to cluster I (12 from169
urine, 9 from blood, 5 from wound and 1 from respiratory tract) and from different170
geographical sources (15 from three hospitals, 8 from the community, and 4 from four171
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long-term care facilities) were evaluated for the presence of ten genes encoding putative172
virulence factors characteristic of extraintestinal pathogenic E. coli using PCR as173
described previously (11). These genes included those encoding S fimbriae (sfaS), F1C174
fimbriae (focG), M blood group antigen-specific M fimbriae (bma), glucosaminyl-175
specific G fimbriae (gaf), Dr family adhesins (afa/dra), toxin associated with176
extraintestinal pathogenic E. coli (cnf1), siderophores as aerobactin (iutA),177
yersiniabactin (fyuA), the serum survival gene (traT), and the invasion of brain178
endothelium gene (ibeA).179
Statistical analyses180
Differences in the prevalence of antibiotic resistance between different groups181
were assessed by Fisher’s exact test. Association was determined by calculation of the182
odds ratio (OR) with 95% confidence intervals (CI). The null hypothesis was rejected183
for values of P < 0.05. Statistical analyses were performed using GraphPad Prism184
version 3.02 software (GraphPad Software, Inc., San Diego, USA).185
186
Results187
Clinical isolates and population study188
From January 2004 to August 2005, a total of 525 unduplicated E. coli ESBL189
producers were collected. Of these isolates, 151 (28.8%) were simultaneously resistant190
to cefotaxime and ceftazidime. Sixty-five (43%) were from males, 84 (55.6%) were191
from females, and two were from patients whose the gender was not reported. Fifteen192
(9.9%) were from children ≤ 14 years of age, 21 (13.9%) were from patients of 15 to 64 193
years of age, and 101 (66.9%) were from patients ≥ 65 years; in 14 cases, the patient’s 194
age was unknown.195
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Of the 151 E. coli isolates, 76 (50.3%) were isolated from the urinary tract, 30196
(19.9%) were from wounds, and 22 (14.6%) were from blood; the remaining 23 cases197
were isolated from other clinical samples (15.2%). Ninety-eight of the patients (64.9%)198
were admitted into different hospital departments: 33 (21.8 %) to internal medicine, 16199
(10.6%) to the emergency room, 12 (7.9%) to pediatric units, 7 (4.6%) to surgery, 5200
(3.3%) to the ICU, and 25 (16.5%) to other departments. Twenty-six patients (17.2%)201
came from long- term care facilities for elderly people, and 21 patients (13.9%) came202
from the community. In six cases, this information was not available.203
In total, 92 isolates (60.9%) produced nosocomial infections (including those204
from nursing homes), 55 (36.4%) produced community-acquired infections, and in 4205
isolates, this information is unknown.206
The clinical diagnoses included urinary tract infections (76 cases or 50.3%),207
wound infection (30 cases or 19.9%), sepsis (22 cases or 14.6%), pneumonia (7 cases or208
4.6%), peritonitis (3 cases or 2%), and abscess (2 cases or 1.3%).209
Seventy-nine patients (52.3%) had predisposing underlying conditions with 21210
cases being respiratory/cardiac diseases (13.9%). Also among these conditions were 16211
cases of impaired immunity (10.6%) (diabetes: 6; tumoral pathology: 4; transplantation:212
3; HIV infection: 2; rheumatic arthritis: 1), 11 cases of cognitive disorders (7.3%), 7213
cases of urinary diseases (4.6%) (including 3 with a vesical catheter), 6 cases of214
premature birth (4%), and 4 cases of liver pathology (2.6%).215
Figure 1 shows the monthly distribution of the 101 E. coli strains that were216
isolated during 2004 in two of the participating hospitals. In the period from January to217
June, 29 (28.7%) cases were detected, and from July to December 72 (71.3%) cases218
were detected (P = 0.02; OR: 0.57, 95% CI: 0.35-0.91).219
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Antimicrobial susceptibility220
Data on antimicrobial susceptibility for all 151 E. coli isolates resistant to221
cefotaxime and ceftazidime are provided in Table 1. The prevalence of antimicrobial222
resistance, calculated according to the MICs, are as follows: 59.9% for223
amoxicillin/clavulanic acid, 38.8% for piperacillin/tazobactam, 98% for cefepime, 8%224
for cefoxitin, 89.3% for ciprofloxacin, 82% for cotrimoxazole, 70% for gentamicin,225
82.7% for tobramycin, and 1.3% for amikacin (Table 1).226
Compared to nosocomial infections, community acquired infections exhibited a227
lower resistance to gentamicin (56.4% vs. 71%; P = 0.001; OR: 0.38, 95% CI: 0.18-228
0.79), and tobramycin (72.2% vs. 87.6%; P = 0.025; OR: 0.36, 95% CI: 0.15-0.86).229
Most of the isolates were resistant to the majority of antibiotics tested. As shown in230
Table 2, 56 of the isolates (37.1%) exhibited multi-resistance pattern A, being231
susceptible to amikacin, cefoxitin, and imipenem. Eleven of the isolates (7.3%) were232
classified as having multi-resistance pattern B, being susceptible to amikacin and233
imipenem. Eleven of the isolates (7.3%) were susceptible to amikacin, cefoxitin,234
imipenem, and gentamicin (pattern C).235
Molecular epidemiology236
Cluster analyses of DNA fingerprinting performed on the 151 isolates is shown237
in Figure 2. XbaI did not digest the DNA of one isolate.238
Using PFGE analysis, four clusters of isolates were detected which exhibited a239
genetic relatedness of 85–100% (Figure 2). One hundred three isolates made up cluster240
I, 11 isolates made up cluster II, 6 isolates made up cluster III, and 5 isolates made up241
cluster IV. The remaining 25 isolates had a genetic similarity of < 85% (Figure 2) and242
were considered unrelated. Cluster I was distributed among all participant centers and243
included nosocomial (65%) and community isolates (35%).244
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Clusters II and IV were distributed among three of the participant centers while245
the six isolates of cluster III belonged exclusively to one of the centers.246
Of the cluster I isolates, three (2.9%) were from children ≤ 14 years of age, 13 247
(12.6%) were from patients of 15 to 64 years of age, and 78 (75.7%) were from patients248
≥ 65 years; in 9 cases, the patient’s age was unknown (Figure 3A).  These isolates 249
caused urinary tract infections in 59 cases (57.3%), wound infections in 21 cases250
(20.4%), sepsis in 15 cases (14.6%), pneumonia in 6 cases (5.8%), and abscesses in 2251
cases (1.9%) (Figure 3B). As shown in Figure 3A, the isolates of cluster I were most252
common in patients ≥ 65 years (75.7% vs. 47.9%; P = 0.0014; OR: 3.4, 95% CI: 1.6-253
6.9). They were also more frequently implicated in urinary tract infections (57.3% vs.254
35.4%; P = 0.0147; OR: 2.4, 95% CI: 1.2-4.9) than other isolates that were resistant to255
cefotaxime and ceftazidime (Figure 3B).256
Cluster I isolates were also significantly more resistant to ciprofloxacin,257
gentamicin, tobramycin, amoxicillin/clavulanic acid, and piperacillin/tazobactam than258
other E. coli isolates (Table 3). However, these isolates exhibited a lower resistance to259
cefoxitin than did other strains (Table 3). Multi-resistance pattern A was the most260
common pattern among the cluster I isolates (46.6%), followed by pattern D (9.7%)261
(Table 2).262
Sixty-seven of the 103 cluster I strains (65%) were collected during 2004 by two263
of the participating hospitals. Sixteen (23.9%) of these strains were isolated between264
January and June, and 51 strains (76.1%) were isolated from July to December (Figure265
1).266
Isoelectric focusing267
Seventy-three E. coli isolates, which included a representative sample of the268
different clusters identified by PFGE and of the unrelated strains, were tested by269
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isoelectric focusing.  Fifty of 73 (68.5%) contained four β-lactamases with apparent pIs 270
equal to 5.4, 6.8, 7.4, and 8.6. The 41 cluster I isolates tested had this profile while only271
10 (31.2%) of the 32 isolates that belonged to other clusters had this profile (P <272
0.0001; OR: 177.9, 95% CI: 9.9-3180).273
Molecular analysis of ESBLs274
All 151 E. coli isolates resistant to cefotaxime and ceftazidime were screened275
with specific CTX-M-10-group primers; DNA from a total of 140 isolates was276
amplified, 133 isolates were identified as containing CTX-M-15, and 7 were identified277
as containing CTX-M-32. The remaining 11 strains were analyzed using universal278
CTX-M-type primers; 5 strains contained CTX-M-14, and 6 did not amplify.279
All isolates of the four clusters as well as 8 (30.8%) of the 26 unrelated isolates280
expressed CTX-M-15. All of the E. coli isolates expressing CTX-M-14- or CTX-M-32-281
exhibited individual PGFE profiles.282
Sequence analysis of PCR products obtained with blaTEM- and blaOXA-1-specific283
primers identified the β-lactamases TEM-1 (pI = 5.4) and OXA-30 (pI = 7.4).  No PCR 284
products were obtained using the blaSHV, blaOXA-2, and blaOXA-10 primers. The band285
corresponding to the pI of 6.8 did not amplify with any of the specific primers for the286
following β-lactamase groups: TEM, SHV, CTX-M, CTX-M-10, OXA-1, OXA-2, 287
OXA-9, OXA-10, OXA-22, OXA-23, OXA-51, and GES-1288
(http://www.lahey.org/studies/webt.asp).289
Eighteen isolates from clusters I, II, III or IV, which expressed CTX-M- 15 were290
analyzed using PROM+ and PRECTX-M-3B primers, as described in Material and291
methods. Cluster I, III, and IV strains yielded PCR products of approximately 1000 bp.292
Further sequencing of this fragment revealed that blaCTX-M-15 was directly linked to an293
upstream ISEcp1-like element, previously implicated in expression and mobilization of294
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CTX-M-15 (13). These isolates failed to yield amplicons using specific primers295
designed to amplify a 400-bp fragment spanning the IS26 element and blaCTX-M-15 – a296
characteristic of the epidemic strain A from the United Kingdom (32). In contrast, 8 of297
the 11 isolates belonging to the cluster II yielded amplicons of approximately 2000 bp298
and contained the fragment spanning the IS26 element and blaCTX-M-15 characteristic of299
strain A (32).300
Identification of additional resistance genes301
The tetA gene was detected in 10 E. coli isolates resistant to tetracycline.302
Resistance to trimethoprim and to sulphamides was associated with a combination of303
sul2 and dfrA14 (8 isolates) or a combination of sul1 and dfrA17 (2 isolates). In304
relation to the aminoglycosidae resistance genes, 7 isolates resistant to both gentamicin305
and tobramycin had aac (6´)-1b and aac (3)-IIb genes. The remaining 3 isolates, which306
were resistant to tobramycin but susceptible to gentamicin, contained only aac (6´)-1b.307
The acrR gene amplified in all 10 isolates examined. Six of these isolates308
exhibited no gene modifications. In contrast, 2 exhibited a single amino acid309
substitution (Gly28Val), and 2 exhibited a single nucleotide deletion (Gua85 and310
Cyt249).311
Virulence factors312
All of the 27 isolates examined harbored the same three virulence genes with313
one exception. Two genes encoded siderophores (iutA and fyuA) and one encoded a314
serum survival factor (traT). One isolate had only the traT gene. None of the genes315




We have previously described significant increases in ESBL production, by both319
nosocomial and community acquired E. coli, in recent years in Spain (21). Other320
worldwide studies have documented similar findings (6,30). This increase has been321
attributed to the rising prevalence of the CTX-M family of ESBLs that has emerged as322
an important and rapidly developing problem worldwide (1,9,25). The first CTX-M-323
type enzyme detected in Spain was CTX-M-9, reported in 1996 (26). In 2003, the first324
report documenting the isolation of a CTX-M-like ESBL in the United States was325
published (9 strains from 5 US States) (27).326
At present, the more prevalent CTX-M-types isolated from clinical samples in327
Spain have been CTX-M-9 and the genetically related CTX-M-14, followed by CTX-328
M-10 (9,17,25). No clonal dissemination of ESBL-producing E. coli was observed in a329
nationwide study of 40 Spanish centers in 2000 (9). CTX-M-15 was not detected in any330
of the three clinical Spanish studies mentioned (9,17,25). Also, CTX-M-15 was not331
detected in one study of fecal carriers performed in Madrid in 2003 (29). All ESBLs332
found were of the CTX-M-9, CTX-M-10, and CTX-M-14 types (29). However, in333
another fecal carrier study from Barcelona (2001-2002), CTX-M-15 was detected in334
five cases, as were both CTX-M-9 and CTX-M-14 (17).335
Data reported here indicate that dissemination of high-level cefotaxime- and336
ceftazidime-resistant E. coli may be attributable to the following. First, the majority of337
resistant isolates were clonally associated and may have caused epidemics in several338
clinical settings. Second, ESBL CTX-M-15 demonstrates the ability to spread among339
different clusters of E. coli. Third, the simultaneous presence of other ESBLs of the340
CTX-M type like CTX-M-32 and CTX-M-14 may produce the same 3rd generation341
cephalosporin resistance profile.342
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The main epidemic E. coli strain was detected in 2004–2005 in isolates from343
patients of very distinct origins, which included three hospitals with a joint catchment344
population of approximately 1,300,000 persons (total population of the Madrid345
Autonomous region is approximately 5.5 million) covering several distinct346
administrative health areas, eight different nursing homes, and one community347
healthcare center. Infection-control measures were reinforced afterwards.348
ESBL CTX-M-15 was first described in New Delhi in 1999 and is carried on349
large plasmids in E. coli, Klebsiella pneumoniae, and Enterobacter aerogenes (13).350
Since then, outbreaks of CTX-M-15 E. coli producers have been described in France,351
the United Kingdom, and Canada (2,15,32). In some studies, the simultaneous presence352
of OXA-30 was also reported (7).353
The great majority of isolates belonging to our epidemic cluster I was from354
urinary tract infections that affect older patients, in accordance with other studies355
(15,19). However, our data may indicate a complex underlying epidemiology of these356
CTX-M-15 producers. The high spreading capacity of CTX-M-15 includes two357
possible scenarios. One is the spread of an epidemic clone with some selective358
advantages (e.g., multiple antibiotic resistance and enhanced virulence) between359
different hospitals, long-term care facilities, and the community; the other is the360
horizontal transfer of plasmids or genes that carry blaCTX-M-15 alleles. Here we361
demonstrate the presence of blaCTX-M-15 within two different genetic environments in the362
same geographical region. The blaCTX-M-15 gene was directly linked to an upstream363
insertion sequence ISEcp1-like element (clusters I, III and IV of this study), as364
described in Canada, Cameroon, and India (2,7,13). In other isolates (8 strains of365
cluster II of this study), an IS26 element was inserted within ISEcp1-like element366
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preceding the blaCTX-M-15 gene, as described in the epidemic strain A of United367
Kingdom (32).368
In addition to β-lactamase resistance mechanisms, CTX-M-15 E. coli producers369
carried an important pool of mobile resistance genes including tetA, dfrA14 or dfrA17,370
sul1 or sul2, aac (6´)-1b, and aac (3)-IIb. Resistance to gentamicin and tobramycin was371
associated with a combination of the aac (6´)-1b and aac (3)-IIb genes, while resistance372
to tobramycin was linked to aac (6´)-1b.373
We also examined possible mutations in acrR, the regulator of the acrAB gene374
encoding a multi-drug efflux pump that has been associated with antimicrobial375
resistance – principally fluoroquinolone resistance (31). Four of the seven multi-376
resistant E. coli isolates tested demonstrated different amino acid substitutions or377
deletions in the acrR system; two of them had an amino acid substitution in a position378
(Gly28) previously described to be connected to norfloxacin, chloramphenicol and379
tetracycline resistance (31). Acquisition of antibiotic resistance may be associated to380
decreased expression of virulence determinants (12). This has also been observed in381
ESBL E. coli producers isolated from urinary tract infections (15). We did not detect382
F1C, S, G and M fimbriae genes by PCR in our strains (that came from non-invasive383
infections in the 86% of the cases); however, the strains isolated from blood also had384
the same virulence genetic profile.385
In this study, 35% of the cluster I isolates were implicated in community-386
acquired infections. With probable origins of hospitals or nursing homes, these findings387
are demonstrative of the disruption of hospital-community barriers. In addition, the388
high and increasing use of fluoroquinolones in Spain and other countries (21) may be389
associated with a co-selection phenomenon, which facilitate the persistence and spread390
of this epidemic strain in fecal flora of healthy carriers. Long-term care centers may391
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represent a significant reservoir for multi-resistant ESBL-producing E. coli isolates, and392
infection control efforts must be addressed in these settings.393
In summary, this study reports the spread of epidemic or occasional resistant E.394
coli isolates between the community, long-term care facilities and hospital settings. It395
also documents the first outbreak of a CTX-M-15 E. coli producer in Spain, affecting396
patients admitted to hospitals, nursing homes, and community outpatient centers. The397
CTX-M-15 extended spectrum β-lactamase was found to be widespread in a main 398
epidemic E. coli strain and also in the majority of other isolates resistant to cefotaxime399
and ceftazidime. The same 3rd generation cephalosporin resistance profile was also due400
to isolates expressing other ESBLs like CTX-M-32 and CTX-M-14. The majority of401
these isolates were found to be susceptible to carbapenems but resistant to the vast402
majority of antibiotics tested.403
Dissemination of these strains type could lead to important changes in the404
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TABLE 1. Antimicrobial susceptibility of 151 Escherichia coli isolates resistant to534
cefotaxime and ceftazidime.535
536
Antibiotic S (%) I (%) R (%) MIC50* MIC90* Range*



































































>2 >2 ≤0.5->2 
Imipenem 151
(100)
0 0 ≤ 1 ≤ 1 ≤ 1 
S: Susceptible; I: Intermediate; R: Resistant.537
* μg/mL.  538
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TABLE 2. Most common multi-resistance patterns found in Escherichia coli isolates539
belonging to cluster I and other isolates resistant to cefotaxime and ceftazidime.540
541
Multi-resistance patterns Cluster I isolates (%) Other isolates (%)
A: Amp-A/Clav-Ctx-Caz-Cef-Pip/Taz-Gen-
Tob-Cip-Sxt
48 (46.6) 8 (16.7)
B: Amp-A/Clav-Ctx-Caz-Cef-Pip/Taz-Gen-
Tob-Cip-Sxt-Fox
6 (5.8) 5 (10.4)
C: Amp-A/Clav-Ctx-Caz-Cef-Pip/Taz-Tob-
Cip-Sxt








Amp: ampicillin, A/Clav: amoxicillin/clavulanic acid, Ctx: cefotaxime, Caz:543
ceftazidime, Cef: cefepime, Pip/Taz: piperacillin/tazobactam, Gen: gentamicin, Tob:544




TABLE 3. Comparison of antimicrobial resistance data between Escherichia coli548








OR 95% CI P
Amoxicillin/Clavulanic acid* 99 (96.1) 39 (81.2%) 5.7 1.7-19.6 0.004
Piperacillin/Tazobactam* 84 (81.6) 28 (58.3) 3.2 1.5-6.7 0.005
Cefoxitin 2 (1.9) 10 (20.8) 0.07 0.02-0.4 0.0002
Ciprofloxacin 99 (96.1) 36 (75) 5.7 1.7-19.6 0.004
Gentamicin 85 (82.5) 22 (45.8) 5.6 2.6-12 <0.0001
Tobramycin 93 (90.3) 32 (66.7) 4.6 1.9-11.3 0.0008
552




FIGURE 1. Monthly distribution of total cases of Escherichia coli isolates belonging to556
cluster I and other isolates resistant to cefotaxime and ceftazidime in two participating557
hospitals during 2004.558
559
FIGURE 2. Dendrogram that illustrates the genetic relationship of 150 ESBL-producing560




FIGURE 3. Comparison of patient’s age (A) and clinical diagnostics (B) between565
Escherichia coli isolates belonging to cluster I and other isolates resistant to cefotaxime566
and ceftazidime.567
568
1: P = 0.001569
2: P = 0.01570
